The clinical trajectory of EYP-1901 marks an overdue transition in ophthalmic medicine: moving away from reactive, high-frequency eye procedures toward durable, sustained-release platforms. For two decades, retinal pharmacology relied on an unsustainable model, asking fragile patients to visit busy medical centers a dozen times a year for invasive eye injections.
The Phase 3 data for DURAVYU confirm that continuous small-molecule delivery can maintain vision over long stretches without regular clinic visits. While retina specialists will continue to debate fluid fluctuations on OCT imaging, the broader takeaway is unambiguous: treatment burden reduction is no longer just a luxury metric. With Phase 3 DME dosing progressing and regulatory reviews approaching, EYP has established that prolonged intracellular VEGF blockade offers an effective path toward keeping eyes functional while giving patients their time back.
